Temat: "fms-Like Tyrosine Kinase 3" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
Autorzy:: Mosquera Orgueira A; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.; University of Santiago de Compostela, Santiago, Spain.
Peleteiro Raíndo A; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.; University of Santiago de Compostela, Santiago, Spain.
Cid López M; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.; University of Santiago de Compostela, Santiago, Spain.
Antelo Rodríguez B; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.; University of Santiago de Compostela, Santiago, Spain.
Díaz Arias JÁ; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.
Ferreiro Ferro R; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.
Alonso Vence N; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.
Bendaña López Á; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.
Abuín Blanco A; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.
Bao Pérez L; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.
Melero Valentín P; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.
González Pérez MS; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.
Cerchione C; University of Bologna, Bologna, Italy.
Martinelli G; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Montesinos Fernández P; University Hospital of La Fe in Valencia, Valencia, Spain.
Pérez Encinas MM; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.; University of Santiago de Compostela, Santiago, Spain.
Bello López JL; Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain.; Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain.; University of Santiago de Compostela, Santiago, Spain.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Feb 16; Vol. 16 (2), pp. e0247093. Date of Electronic Publication: 2021 Feb 16 (Print Publication: 2021).
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia/*genetics
Leukemia, Myeloid, Acute/*genetics
Mutation/*genetics
fms-Like Tyrosine Kinase 3/*genetics
Biomarkers/metabolism ; DNA (Cytosine-5-)-Methyltransferases/genetics ; DNA Methyltransferase 3A ; Gene Expression Profiling/methods ; Humans ; Nuclear Proteins/genetics ; Nucleophosmin ; Staurosporine/analogs & derivatives ; Staurosporine/pharmacology ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
Autorzy:: Patel RK; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Weir MC; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Shen K; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Snyder D; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Cooper VS; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Smithgall TE; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Dec 02; Vol. 14 (12), pp. e0225887. Date of Electronic Publication: 2019 Dec 02 (Print Publication: 2019).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/enzymology
Leukemia, Myeloid, Acute*/genetics
Mutation, Missense*
Proto-Oncogene Proteins*/biosynthesis
Proto-Oncogene Proteins*/genetics
Proto-Oncogene Proteins c-hck*/biosynthesis
Proto-Oncogene Proteins c-hck*/genetics
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
fms-Like Tyrosine Kinase 3*/genetics
fms-Like Tyrosine Kinase 3*/metabolism
src-Family Kinases*/biosynthesis
src-Family Kinases*/genetics
Drug Resistance, Neoplasm/*drug effects
Gene Expression Regulation, Developmental/*drug effects
Gene Expression Regulation, Leukemic/*drug effects
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Pyrroles/*pharmacology
Amino Acid Substitution ; Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; Humans ; Prognosis ; Exome Sequencing

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Fast in-vitro screening of FLT3-ITD inhibitors using silkworm-baculovirus protein expression system.
Autorzy:: Yamamoto N; Division of Biophysics, Department of Physiology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Kikuchi J; Division of Stem Cell Regulation, Center for Molecular Medicine, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Furukawa Y; Division of Stem Cell Regulation, Center for Molecular Medicine, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Shibayama N; Division of Biophysics, Department of Physiology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2022 May 05; Vol. 17 (5), pp. e0261699. Date of Electronic Publication: 2022 May 05 (Print Publication: 2022).
Typ publikacji:: Journal Article
MeSH Terms:: Bombyx*/genetics
Leukemia, Myeloid, Acute*/genetics
Animals ; Baculoviridae ; Mutation ; Protein Kinase Inhibitors/pharmacology ; fms-Like Tyrosine Kinase 3/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Regulation of the Flt3 Gene in Haematopoietic Stem and Early Progenitor Cells.
Autorzy:: Volpe G; Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Clarke M; Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Garcìa P; Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Walton DS; Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Vegiopoulos A; DKFZ Junior Group Metabolism and Stem Cell Plasticity, Division of Molecular Metabolic Control (A170), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Del Pozzo W; School of Physics and Astronomy, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
O'Neill LP; Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Frampton J; Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Dumon S; Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Sep 18; Vol. 10 (9), pp. e0138257. Date of Electronic Publication: 2015 Sep 18 (Print Publication: 2015).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: CCAAT-Enhancer-Binding Proteins/*physiology
Hematopoietic Stem Cells/*metabolism
Oncogene Proteins v-myb/*physiology
fms-Like Tyrosine Kinase 3/*genetics
Animals ; CCAAT-Enhancer-Binding Proteins/genetics ; Cell Differentiation/genetics ; Cell Lineage/genetics ; Cells, Cultured ; Gene Expression Regulation ; Hematopoiesis/genetics ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Oncogene Proteins v-myb/genetics ; fms-Like Tyrosine Kinase 3/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
Autorzy:: Zorn JA; Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America; California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America.
Wang Q; Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America; California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America.
Fujimura E; Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America.
Barros T; Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America; California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America; Howard Hughes Medical Institute, University of California, Berkeley, California, United States of America.
Kuriyan J; Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America; California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America; Howard Hughes Medical Institute, University of California, Berkeley, California, United States of America; Department of Chemistry, University of California, Berkeley, California, United States of America; Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Apr 02; Vol. 10 (4), pp. e0121177. Date of Electronic Publication: 2015 Apr 02 (Print Publication: 2015).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*chemistry
Benzothiazoles/*chemistry
Neoplasm Proteins/*chemistry
Phenylurea Compounds/*chemistry
Protein Kinase Inhibitors/*chemistry
Recombinant Fusion Proteins/*chemistry
fms-Like Tyrosine Kinase 3/*chemistry
Animals ; Baculoviridae/genetics ; Catalytic Domain ; Crystallography, X-Ray ; Humans ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Mutation ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/genetics ; Protein Binding ; Protein Folding ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Recombinant Fusion Proteins/genetics ; Sf9 Cells ; Spodoptera/genetics ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.
Autorzy:: Yu C; Department Medicine I, University Medical Center Freiburg, Freiburg, Germany.
Kancha RK; Department Medicine I, University Medical Center Freiburg, Freiburg, Germany.
Duyster J; Department Medicine I, University Medical Center Freiburg, Freiburg, Germany.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 May 21; Vol. 9 (5), pp. e97116. Date of Electronic Publication: 2014 May 21 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Gene Expression Regulation, Leukemic*
Benzoquinones/*pharmacology
HSP90 Heat-Shock Proteins/*antagonists & inhibitors
Lactams, Macrocyclic/*pharmacology
fms-Like Tyrosine Kinase 3/*genetics
Amino Acid Sequence ; Animals ; Cell Line, Tumor ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; HSP90 Heat-Shock Proteins/genetics ; HSP90 Heat-Shock Proteins/metabolism ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Mice ; Molecular Sequence Data ; Mutation ; Protein Binding ; Protein Kinase Inhibitors/pharmacology ; Protein Stability/drug effects ; Protein Structure, Tertiary ; Proteolysis ; Sequence Alignment ; Signal Transduction ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Autorzy:: Lin WH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Yeh TK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Jiaang WT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Yen KJ; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Chen CH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Huang CT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Yen SC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Hsieh SY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Chou LH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Chen CP; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Chiu CH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Kao LC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Chao YS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Chen CT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Hsu JT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan ; Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 Jan 08; Vol. 9 (1), pp. e83160. Date of Electronic Publication: 2014 Jan 08 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Benzamides/*therapeutic use
Histone Deacetylase Inhibitors/*therapeutic use
Hydroxamic Acids/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Urea/*analogs & derivatives
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Animals ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Apoptosis/drug effects ; Benzamides/chemistry ; Benzamides/pharmacokinetics ; Benzamides/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Histone Deacetylase Inhibitors/pharmacology ; Hydroxamic Acids/pharmacology ; Leukemia, Myeloid, Acute/enzymology ; Leukemia, Myeloid, Acute/pathology ; Male ; Mice ; Mice, Nude ; Protein Kinase Inhibitors/pharmacology ; Rats ; Signal Transduction/drug effects ; Urea/chemistry ; Urea/pharmacokinetics ; Urea/pharmacology ; Urea/therapeutic use ; Vorinostat ; fms-Like Tyrosine Kinase 3/metabolism